Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
27 10 2020
27 10 2020
Historique:
received:
06
04
2020
accepted:
11
09
2020
entrez:
27
10
2020
pubmed:
28
10
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Colony-stimulating factor 3 receptor (CSF3R) encodes the receptor for granulocyte colony-stimulating factor (G-CSF), a cytokine vital for granulocyte proliferation and differentiation. Acquired activating heterozygous variants in CSF3R are the main cause of chronic neutrophilic leukemia, a hyperproliferative disorder. In contrast, biallelic germ line hypomorphic variants in CSF3R are a rare cause of severe congenital neutropenia, a hypoproliferative condition. The impact of heterozygous germ line CSF3R variants, however, is unknown. We identified CSF3R as a new germ line hematologic malignancy predisposition gene through analysis of 832 next-generation sequencing tests conducted in 632 patients with hematologic malignancies. Among germ line CSF3R variants, 3 were abnormal in functional testing, indicating their deleterious nature. p.Trp547* was identified in 2 unrelated men with myelodysplastic syndromes diagnosed at 76 and 33 years of age, respectively. p.Trp547* is a loss-of-function nonsense variant in the extracellular domain that results in decreased CSF3R messenger RNA expression and abrogation of CSF3R surface expression and proliferative responses to G-CSF. p.Ala119Thr is a missense variant found in 2 patients with multiple myeloma and acute lymphoblastic leukemia, respectively. This variant is located between the extracellular immunoglobulin-like and cytokine receptor homology domains and results in decreased G-CSF sensitivity. p.Pro784Thr was identified in a 67-year-old man with multiple myeloma. p.Pro784Thr is a missense variant in the cytoplasmic domain that inhibits CSF3R internalization, producing a gain-of-function phenotype and G-CSF hypersensitivity. Our findings identify germ line heterozygous CSF3R variants as risk factors for development of myeloid and lymphoid malignancies.
Identifiants
pubmed: 33108454
pii: S2473-9529(20)31921-2
doi: 10.1182/bloodadvances.2020002013
pmc: PMC7594406
doi:
Substances chimiques
CSF3R protein, human
0
Receptors, Colony-Stimulating Factor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5269-5284Informations de copyright
© 2020 by The American Society of Hematology.
Références
Leuk Res. 1996 Aug;20(8):629-31
pubmed: 8913314
Front Biosci. 2007 Jan 01;12:800-15
pubmed: 17127321
Cancer Genet. 2019 Jun;235-236:84-92
pubmed: 31101556
Blood. 2009 May 28;113(22):5583-7
pubmed: 19357396
J Biol Chem. 2001 Sep 28;276(39):36779-87
pubmed: 11468284
Front Immunol. 2019 Feb 28;10:116
pubmed: 30891028
Leuk Lymphoma. 2010 Oct;51(10):1931-5
pubmed: 20846103
PLoS Genet. 2017 Aug 7;13(8):e1006925
pubmed: 28787443
Cancer Res. 2018 Dec 15;78(24):6762-6770
pubmed: 30348809
Leukemia. 2004 Sep;18(9):1553-5
pubmed: 15284863
Blood. 2014 Jun 12;123(24):3811-7
pubmed: 24753537
Blood. 2001 Feb 1;97(3):829-30
pubmed: 11227095
Br J Haematol. 2002 Jul;118(1):296-304
pubmed: 12100165
N Engl J Med. 2013 May 9;368(19):1781-90
pubmed: 23656643
Int J Hematol. 2017 Aug;106(2):189-195
pubmed: 28555414
J Exp Med. 2009 Aug 3;206(8):1701-7
pubmed: 19620628
Exp Hematol. 2017 Feb;46:9-20
pubmed: 27789332
EMBO J. 2007 Apr 4;26(7):1782-93
pubmed: 17363902
PLoS Genet. 2016 Aug 04;12(8):e1006236
pubmed: 27490902
Blood. 2004 Aug 1;104(3):667-74
pubmed: 15069015
J Biol Chem. 2018 May 11;293(19):7387-7396
pubmed: 29572350
Blood. 1999 Jan 15;93(2):440-6
pubmed: 9885205
Blood. 2010 Jun 24;115(25):5131-6
pubmed: 20237318
Blood. 1997 Apr 1;89(7):2369-75
pubmed: 9116280
Biochem Biophys Res Commun. 2020 Feb 26;523(1):208-213
pubmed: 31848046
Blood. 2016 Feb 25;127(8):1017-23
pubmed: 26712909
Blood. 2016 Oct 20;128(16):2097-2099
pubmed: 27581359
Leukemia. 2013 Sep;27(9):1870-3
pubmed: 23604229
Blood. 2017 Feb 9;129(6):715-722
pubmed: 28028025
Blood. 2004 Apr 15;103(8):3226-9
pubmed: 15070707
Blood. 1999 Jan 15;93(2):447-58
pubmed: 9885206
J Mol Diagn. 2017 Jan;19(1):43-56
pubmed: 27836695
Cell. 2016 Nov 17;167(5):1415-1429.e19
pubmed: 27863252
Blood. 2015 Oct 8;126(15):1865-7
pubmed: 26324699
Leuk Lymphoma. 2014 Jul;55(7):1661-2
pubmed: 24033109
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3135-40
pubmed: 16492764
Blood. 2004 Jan 15;103(2):571-9
pubmed: 14512302
Leukemia. 2013 Sep;27(9):1946-9
pubmed: 23774674
Clin Cancer Res. 2016 Feb 1;22(3):757-64
pubmed: 26475333
J Mol Diagn. 2018 Jan;20(1):123-125
pubmed: 29249243
Blood. 2009 Jan 15;113(3):668-70
pubmed: 19020310
Blood. 2018 Jan 18;131(3):373
pubmed: 29348313
Nat Biotechnol. 2001 May;19(5):434-9
pubmed: 11329012
Blood. 2019 Sep 12;134(11):867-879
pubmed: 31366621
Blood. 2019 Oct 24;134(17):1441-1444
pubmed: 31484648
Blood. 2014 Apr 3;123(14):2229-37
pubmed: 24523240
Blood Adv. 2020 Mar 24;4(6):1131-1144
pubmed: 32208489
Cancer. 2018 Aug;124(16):3329-3338
pubmed: 29932212
Am J Hematol. 2019 Jul;94(7):757-766
pubmed: 30963592
Genet Mol Biol. 2019;42(1 suppl 1):215-231
pubmed: 31067289
Blood. 2019 Dec 26;134(26):2414-2416
pubmed: 31697825
Sci Rep. 2015 Jan 12;5:7729
pubmed: 25578556